No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
RCKT240517P17500
- 0.27
- 0.000.00%
15min DelayClose Apr 5 12:03 ET
0.00High0.00Low
0.00Open0.27Pre Close0 Volume0 Open Interest17.50Strike Price0.00Turnover2682.16%IV-20.67%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier-6DDays to Expiry0.27Time Value100Contract SizeAmericanOptions Type-0.1026Delta0.0356Gamma80.44Leverage Ratio-17.7802Theta0.0000Rho-8.25Eff Leverage0.0003Vega
Intraday
- 5D
- 1D
News
Buy Rating on Rocket Pharmaceuticals Amidst Positive Outlook and Strategic Execution
Cantor Picks 14 Undervalued Biotech Stocks Worth a Second Look
Express News | Rocket Pharmaceuticals Inc : UBS Cuts Target Price to $51 From $54
Rocket Pharmaceuticals Says Blood Disorder Therapies Show Promise
Rocket Pharmaceuticals (RCKT) said Friday that longer-term data on its experimental gene therapies to treat patients with rare blood disorders showed sustained safety and efficacy. Kresladi, a treatme
Rocket Pharmaceuticals Presents Longer-Term Data Updates From Its Lentiviral Vector Hematology Portfolio At ASGCT
Long-term KRESLADI follow-up data demonstrate survival of 100% in the absence of allogeneic hematopoietic stem cell transplantation (HSCT) from 18 to 45 months with a well-tolerated safety profile in
Express News | Rocket Pharmaceuticals Inc - Well-Tolerated Safety Profile in Pkd Patients up to 36 Months After Rp-L301 Treatment
Comments
See remaining FDA PDUFAs in May 👀👇
$Bristol-Myers Squibb(BMY.US$ : Breyanzi
‣ PDUFA date: 5/31/24 (sBLA)
$Moderna(MRNA.US$ : mRNA-1345
‣ PDUFA date: End of May 2024 (est.) (BLA)
📣 Buckle up & get ready for next month...
June brings 17 PDUFA decisions: 🔥 🔥
$Catalyst Pharmaceuticals(CPRX.US$ : FIRDAPSE® (Amifampridine)
$GlaxoSmithKline(GSK.US$ : Arexvy
$Genfit(GNFT.US$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD(IPSEY.US$ : Elafibranor
$Regeneron Pharmaceuticals(REGN.US$ : Kevzara (sarilumab)
$Bristol-Myers Squibb(BMY.US$ : Augtyro...
$Bristol-Myers Squibb(BMY.US$ : Breyanzi
‣ PDUFA date: 5/31/24 (sBLA)
$Moderna(MRNA.US$ : mRNA-1345
‣ PDUFA date: End of May 2024 (est.) (BLA)
📣 Buckle up & get ready for next month...
June brings 17 PDUFA decisions: 🔥 🔥
$Catalyst Pharmaceuticals(CPRX.US$ : FIRDAPSE® (Amifampridine)
$GlaxoSmithKline(GSK.US$ : Arexvy
$Genfit(GNFT.US$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD(IPSEY.US$ : Elafibranor
$Regeneron Pharmaceuticals(REGN.US$ : Kevzara (sarilumab)
$Bristol-Myers Squibb(BMY.US$ : Augtyro...
2
1
$Rocket Pharmaceuticals(RCKT.US$ Reuters· 2 mins ago
Rocket Pharmaceuticals Inc - Well-Tolerated Safety Profile in Pkd Patients up to 36 Months After Rp-L301 Treatment
Rocket Pharmaceuticals Inc - Well-Tolerated Safety Profile in Pkd Patients up to 36 Months After Rp-L301 Treatment
1
Several highly anticipated PDUFA decisions are approaching..👇
Abeona Therapeutics ( $Abeona Therapeutics(ABEO.US$ )
Asset: Pz-cel (prademagene zamikeracel)
PDUFA Date: May 25, 2024
Indication: Recessive dystrophic epidermolysis bullosa (RDEB)
Technology: Autologous cell therapy, treatment uses gene transfer to deliver COL7A1 genes into an RDEB patient’s own skin cells then transplanting them back to the patient.
Rocket Pharmaceuticals ( $Rocket Pharmaceuticals(RCKT.US$ )...
Abeona Therapeutics ( $Abeona Therapeutics(ABEO.US$ )
Asset: Pz-cel (prademagene zamikeracel)
PDUFA Date: May 25, 2024
Indication: Recessive dystrophic epidermolysis bullosa (RDEB)
Technology: Autologous cell therapy, treatment uses gene transfer to deliver COL7A1 genes into an RDEB patient’s own skin cells then transplanting them back to the patient.
Rocket Pharmaceuticals ( $Rocket Pharmaceuticals(RCKT.US$ )...
7
Read more
Srav Reddy : Any idea $Akoya Biosciences (AKYA.US)$ drop 35% this week